Omalizumab for Difficult-to-Treat Dermatological Conditions: Clinical and Immunological Features from a Retrospective Real-Life Experience-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Omalizumab for Difficult-to-Treat Dermatological Conditions: Clinical and Immunological Features from a Retrospective Real-Life Experience

Published:2015-01-13 Issue:3 Volume:35 Page:159-168
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Romano Ciro,Sellitto Ausilia,De Fanis Umberto,Balestrieri Antonella,Savoia Alfonso,Abbadessa Salvatore,Astarita Corrado,Lucivero Giacomo

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s40261-015-0267-9.pdf

Reference46 articles.

1. Humbert N, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309–16.

2. Chang TW, Wu PC, Hsu CL, Hung AF. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Adv Immunol. 2007;93:63–119.

3. Chang TW, Shiung YY. Anti-IgE as a mast cell-stabilizing therapeutic agent. J Allergy Clin Immunol. 2006;117:1203–13.

4. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126:466–76.

5. Tsabouri S, Tseretopoulou X, Priftis K, Ntzani EE. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol Pract. 2014;2:332–40.

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Off-label use of Baricitinib improves moderate and severe atopic dermatitis in China through inhibiting MAPK and PI3K/Akt/mTOR pathway via targeting JAK-STAT signaling of CD4+ cells;Frontiers in Pharmacology;2024-02-29

2. Chronic Refractory Idiopathic Urticaria;Journal of Biosciences and Medicines;2023

3. Emerging Targeted Treatments;Atopic Dermatitis : Inside Out Or Outside in;2023

4. Management of Severe Asthma in Eosinophilic Granulomatosis with Polyangiitis with Interleukin-5-Targeted Therapies: Current Status and Report of Two Cases;Applied Sciences;2022-11-14

5. Prevalence, Clinical Manifestations, Treatment, and Clinical Course of Chronic Urticaria in Elderly: A Systematic Review;Journal of Asthma and Allergy;2022-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3